JAN 12, 2021 10:58 AM PST

SGLT2 Inhibitors Can Reduce the Cardiovascular Risk for Diabetics Being Treated with Insulin

WRITTEN BY: Jasper Cantrell

One of the biggest problems that come alongside diabetes is the increased risk of cardiovascular disease. Treatment of diabetes often reduces the risk, but some scientists wonder if the treatments reduce the risk by treating diabetes or directly affecting the cardiovascular system.

One of the go-to treatments for type 2 diabetes is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This protein is a regulator of sugar in the blood, and its inhibition can increase the amount of sugar excreted by the bladder. Dapagliflozin, empagliflozin, and canagliflozin are all drugs that use this mechanism to control sugar levels in diabetic patients. Still, some recent evidence suggests these may also independently reduce the risk of cardiovascular disease.

In a new study, a team from the University Medical Center Hamburg-Eppendorf in Germany wanted to investigate further. A few recent studies have shown that SGLT2 inhibitors lowered the risk of cardiovascular hospitalization or death in patients with diabetes. However, these studies were conducted in the absence of insulin, a common diabetes treatment. This new study investigated whether the reduced cardiovascular risk could also be seen in patients treated with insulin.

To do this, the team examined the cardiovascular biomarkers hematocrit, red blood cell count, and reticulocyte in a double-blind, randomized trial. All are indicators of cardiovascular risk. Enrolled patients were being treated with insulin and were put in either a placebo group or given a certain dose of the SGLT2 inhibitor dapagliflozin.

The study found that dapagliflozin treatment increased both hematocrit levels in the blood and red blood cell count across the 104-week trial. Reticulocytes, a precursor to red blood cells, increased during the first 4-weeks but then dropped back down to levels akin to the placebo group. These results suggest that SGLT2 inhibitors have the same effect against cardiovascular risk in diabetic patients treated with insulin as they do with patients not being treated with insulin.

This study followed markers of cardiovascular risk during dapagliflozin treatment in a group of diabetic patients already being treated with insulin. They did not independently measure the onset of cardiovascular disease in their study, however previous studies had found that the increases to hematocrit, red blood cell count, and reticulocytes correlate well with a reduced cardiovascular risk in diabetic patients.  

The study concludes, “In summary, we show that dapagliflozin induces a long-term and dose-dependent elevation in haematocrit that is preserved in patients receiving concomitant insulin treatment, including chronic insulin therapy.”

Sources: Nature Scientific Reports, AJMCtv

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
APR 14, 2021
Cardiology
Activity At Work Doesn't Benefit Like Leisure Time Exercise
APR 14, 2021
Activity At Work Doesn't Benefit Like Leisure Time Exercise
A new study that examined the habits and health conditions of thousands of people has suggested that exercise that's don ...
JUL 19, 2021
Cardiology
Immune Proteins & Blood Clots May be Connected to Psychosis Development
JUL 19, 2021
Immune Proteins & Blood Clots May be Connected to Psychosis Development
Researchers are pointing out the associations between blood clotting disruptions and the front line immune system, and t ...
AUG 03, 2021
Health & Medicine
Viruses and Autoimmunity: What Pandemics Have Taught Us
AUG 03, 2021
Viruses and Autoimmunity: What Pandemics Have Taught Us
COVID-19 infections have given rise to COVID long haulers, people who had COVID and continue to have symptoms months aft ...
AUG 19, 2021
Cardiology
How Gut Microbes May Link a High-Fat Diet and Heart Disease
AUG 19, 2021
How Gut Microbes May Link a High-Fat Diet and Heart Disease
Cardiovascular disease is the leading cause of death around the world. Atherosclerosis is known to be a major contributo ...
SEP 29, 2021
Health & Medicine
Does Exercise Accelerate Atherosclerosis?
SEP 29, 2021
Does Exercise Accelerate Atherosclerosis?
The last thing anyone expects an athlete to die of is a heart attack. It happened to Jim Fixx, running aficionado and be ...
OCT 07, 2021
Health & Medicine
A School-based Approach to Combatting Adolescent Obesity
OCT 07, 2021
A School-based Approach to Combatting Adolescent Obesity
It should come as no surprise that obesity is a significant public health concern associated with astronomical economic ...
Loading Comments...